Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Movetis (Vosselaar, Belgium) said oral Resolor prucalopride met the primary endpoint of the proportion
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury